This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
HF IMPACT Banner

ATTR-CM & Carpal Tunnel Syndrome

Dr Yousef Razvi at British Society for Heart Failure

Transthyretin amyloid cardiomyopathy (ATTR-CM) is often missed early - patients experience a delay in diagnosis of between 2-6 years.
 The signs are often missed because symptoms are similar to those of other common diseases, yet early detection remains a significant unmet need, because earlier intervention improves outcomes in these patients.

 

Carpal tunnel syndrome can be a very early sign
, manifesting in 33–49% of ATTR-CM patients several years before cardiac symptoms appear.

In this 9-minute video,

Dr Yousuf Razvi
(Senior Clinical Fellow, National Amyloidosis Center, Royal Free Hospital, London) presents at the British Society of Heart Failure on the long-term UK prospective multicentre study ‘Educate’ – Early diagnosis of transthyretin amyloid cardiomyopathy using carpal tunnel biopsy examination. The study sought to understand if utilising biopsies at the time of routine carpal tunnel decompression can facilitate earlier diagnosis of ATTR-CM.

Prescribing information for BEYONTTRA®▼ (acoramidis)
can be found here
.

You may also be interested in:

Bey - Thumbnail
Beyonttra®▼ (acoramidis) - Overview
About Beyonttra
PP-BEY-GB-0213, March 2026
CV Summit 2025 - ATTR-CM Highlight Content Card
Cardiovascular Summit 2025 - ATTR-CM Highlights
Explore the Key Highlights on Transthyretin Amyloid Cardiomyopathy (ATTR-CM) | Beyonttra®▼ (acoramidis)
PP-BEY-GB-0085, November 2025
Navigation ATTR-CM Diagnosis resources
Navigating ATTR-CM Diagnosis
Beyonttra®▼ (acoramidis) | Explore resources on Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
PP-PF-CAR-GB-0060, October 2025
HF-IMPACT Hub
HF-IMPACT Hub
Explore Resources and Events Focussed on Improving Management and Prognosis Through Advance Cardiac Training
PP-BEY-GB-0074, October 2025
Register for BayerPRO - Beyonttra

Register for BayerPRO

Stay up to date on future events and webinars posted by registering to BayerPRO here.

Register Now

Prescribing information for BEYONTTRA®▼ (acoramidis)
can be found here
.

 

Abbreviation:

ATTR-CM, Transthyretin Amyloid Cardiomyopathy.

 

PP-BEY-GB-0226 | March 2026

    • 1
      Rozenbaum MH, et al. Cardiol Ther. 2021;10(1):141–159.
    • 2
      Lane T, et al. Circulation. 2019;140(1):16–26.
    • 3
      Maurer MS, et al. Circ Heart Fail. 2019;12(9):e006075.
    • 4
      Brito D, et al. Global Heart. 2023;18(1):59.
    • 5
      Gonzalez-Lopez E, et al. Rev Esp Cardiol. 2017;70(11):991–1004.
    • 6
      Razvi Y, et al. J Am Coll Cardiol. 2025;85(12):4694.